Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.70 |
| ▸ | SCN5A | Q14524 | 10/20 | 0.70 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.47 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.47 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.47 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121689 | 0.86 | SCN9A (0.72) | SCN9ASCN5AS1PR1 | |
| SCHEMBL19475805 | 0.86 | SCN9A (0.69) | SCN9ASCN5A | |
| SCHEMBL23796215 | 0.86 | SCN5A (0.54) | SCN9ASCN5ACYP2C8TEAD1TEAD4 | |
| SCHEMBL30290067 | 0.86 | SCN5A (0.54) | SCN9ASCN5ACYP2C8TEAD1TEAD4 | |
| SCHEMBL121650 | 0.85 | IDO1 (0.58) | SCN9ASCN5AS1PR1 | |
| SCHEMBL121474 | 0.84 | SCN9A (0.68) | SCN9ASCN5AS1PR1 | |
| SCHEMBL19475849 | 0.83 | SCN9A (1.00) | SCN9ASCN5A | |
| SCHEMBL23796079 | 0.82 | SCN5A (0.50) | SCN9ASCN5ACYP2C8TEAD1TEAD4 | |
| SCHEMBL19475709 | 0.82 | SCN9A (0.70) | SCN9ASCN5A | |
| SCHEMBL19475918 | 0.82 | SCN9A (1.00) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550080-B2 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550080-B2 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190119209-A1 | ACYL SULFONAMIDE NaV1.7 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190119209-A1 | ACYL SULFONAMIDE NaV1.7 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-25 | — | — | US | disclosed |
| WO-2017184658-A1 | ACYL SULFONAMIDE NaV1.7 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184658-A1 | ACYL SULFONAMIDE NaV1.7 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-26 | — | — | WO | disclosed |
| EP-2611774-B1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-18 | — | — | EP | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | disclosed |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| WO-2010124082-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124112-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124116-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124102-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124119-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124114-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124108-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124086-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550080-B2 | Acyl sulfonamide NaV1.7 inhibitors | SCN7A, SCN1A, SCN8A | SCN9A 10/4885SCN5A 7/4885S1PR1 2387/4885 |
| US-20190119209-A1 | ACYL SULFONAMIDE NaV1.7 INHIBITORS | SCN7A, SCN1A, SCN8A | SCN9A 10/4885SCN5A 7/4885S1PR1 2387/4885 |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | SCN9A 775/4885SCN5A 1495/4885S1PR1 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.